Nicox S.A.
https://www.nicox.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nicox S.A.
Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.
Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Topical Delivery
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Laboratoires Doliage
- Eupharmed srl
- Aciex Therapeutics, Inc.
- AVEye Biotechnologie GmbH